> The HB vaccine unfortunately doesn't work that well, many people are still not fully immune even after several doses
This is incorrect. The HBV vaccine is one of the most effective vaccines available for any pathogen, providing full immunity to over 95% of healthy infants, children, and young adults, and with that immunity typical lasting for at least 30 years (and likely for life).
If someone is one of the rare exception, tthat's easy to detect with blood titers, and the response is either to give them additional doses or to deliver an adjuvanted version (which is the same thing regularly done for other vaccines which are either less effective or primarily targeted at the elderly, who have weaker immune responses).
I work in healthcare. As a requirement for employment, I had to get tested for immunity to HBV. Even though I got the vaccine as is generally recommended for everyone, the test says I'm not immue. So now I have to get 3 additional doses, and apparently even with that it's not guaranteed sufficient for full immunity. And I know my case is not unusual at all
One 20 is not unusual. That said, that does not mean that the vaccine is not effective at being a vaccine. A vaccine isnt just about your immunity, but about herd immunity. When you create an inability for a virus to spread among the herd, you protect those who are unable to acquire immunity by inhibiting the viruses ability to move between hosts and persist in a population.
Vaccines are not 100% effective for each individual.
This is incorrect. The HBV vaccine is one of the most effective vaccines available for any pathogen, providing full immunity to over 95% of healthy infants, children, and young adults, and with that immunity typical lasting for at least 30 years (and likely for life).
If someone is one of the rare exception, tthat's easy to detect with blood titers, and the response is either to give them additional doses or to deliver an adjuvanted version (which is the same thing regularly done for other vaccines which are either less effective or primarily targeted at the elderly, who have weaker immune responses).